Molecular‐targeted nanotherapies in cancer: Enabling treatment specificity
- 25 October 2011
- journal article
- review article
- Published by Wiley in Molecular Oncology
- Vol. 5 (6) , 492-503
Abstract
Chemotherapy represents a mainstay and powerful adjuvant therapy in the treatment of cancer. The field has evolved from drugs possessing all‐encompassing cell‐killing effects to those with highly targeted, specific mechanisms of action; a direct byproduct of enhanced understanding of tumorigenic processes. However, advances regarding development of agents that target key molecules and dysregulated pathways have had only modest impacts on patient survival. Several biological barriers preclude adequate delivery of drugs to tumors, and remain a formidable challenge to overcome in chemotherapy. Currently, the field of nanomedicine is enabling the delivery of chemotherapeutics, including repositioned drugs and siRNAs, by giving rise to carriers that provide for protection from degradation, prolonged circulation times, and increased tumor accumulation, all the while resulting in reduced patient morbidity. This review aims to highlight several innovative, nanoparticle‐based platforms with the potential of providing clinical translation of several novel chemotherapeutic agents. We will also summarize work regarding the development of a multistage drug delivery strategy, a robust carrier platform designed to overcome several biological barriers while en route to tumors.Keywords
Funding Information
- DOD/BCRP (W81XWH-09-1-0212)
- DOD/BCRP (W81XWH-11-1-0103)
This publication has 77 references indexed in Scilit:
- Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycinInternational Journal of Pharmaceutics, 2011
- Peaking beneath the surface of recent bevacizumab trialsNature Reviews Clinical Oncology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Tailoring the degradation kinetics of mesoporous silicon structures through PEGylationJournal of Biomedical Materials Research Part A, 2010
- Frontiers in cancer nanomedicine: directing mass transport through biological barriersTrends in Biotechnology, 2010
- Tailored Porous Silicon Microparticles: Fabrication and PropertiesChemphyschem, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Bioconjugated quantum dots for in vivo molecular and cellular imaging☆Advanced Drug Delivery Reviews, 2008
- β-Lapachone-containing PEG–PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cellsJournal of Controlled Release, 2007
- The Hallmarks of CancerCell, 2000